Addex Therapeutics (ADXN) Retained Earnings (2018 - 2026)
Addex Therapeutics (ADXN) posted Retained Earnings of -$462.0 million for Q1 2026, down 2.55% sequentially from -$450.5 million in Q4 2025, and down 17.07% YoY from -$557.1 million in Q1 2025.
Addex Therapeutics (ADXN) Retained Earnings (2018 - 2026) Analysis & Trends
Addex Therapeutics has reported Retained Earnings for 9 years, with the latest figure at -$462.0 million in Q1 2026.
- Quarterly Retained Earnings fell 17.07% year-over-year to -$462.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$462.0 million (down 17.07% YoY) and the FY2025 annual result came in at -$434.3 million, down 8.13% from the prior year.
- Retained Earnings slipped to -$462.0 million in Q1 2026 per ADXN's latest filing, from -$450.5 million in the prior quarter.
- Over five years, Retained Earnings peaked at -$355.2 million in Q2 2022 and troughed at -$462.0 million in Q1 2026.
- A 5-year average of -$401.5 million and a median of -$403.4 million in 2024 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2025 and 2026: Retained Earnings gained 5.23% in 2025, then decreased 17.07% in 2026.
- Over 5 years, Retained Earnings stood at -$363.2 million in 2022, then decreased by 11.88% to -$406.3 million in 2023, then gained by 0.73% to -$403.4 million in 2024, then slipped by 11.69% to -$450.5 million in 2025, then fell by 2.55% to -$462.0 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$462.0 million, -$450.5 million, and -$447.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Addex Therapeutics | 534.71 Mn | 534.71 Mn | - | -462.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -462.02 Mn |
| Dec 31, 2025 | -450.53 Mn |
| Sep 30, 2025 | -447.86 Mn |
| Jun 30, 2025 | -430.83 Mn |
| Mar 31, 2025 | -394.67 Mn |
| Dec 31, 2024 | -403.37 Mn |
| Sep 30, 2024 | -406.46 Mn |
| Jun 30, 2024 | -387.72 Mn |
| Mar 31, 2024 | -416.46 Mn |
| Dec 31, 2023 | -406.32 Mn |
| Sep 30, 2023 | -404.81 Mn |
| Jun 30, 2023 | -394.76 Mn |
| Mar 31, 2023 | -380.86 Mn |
| Dec 31, 2022 | -363.16 Mn |
| Sep 30, 2022 | -358.49 Mn |
| Jun 30, 2022 | -355.20 Mn |
| Mar 31, 2022 | -362.61 Mn |
| Dec 31, 2021 | -356.86 Mn |
| Sep 30, 2021 | -353.57 Mn |
| Jun 30, 2021 | -352.06 Mn |